{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:13:20Z","timestamp":1793157200733,"version":"4.5.0"},"reference-count":88,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","award":["B.SUB.25.318"],"award-info":[{"award-number":["B.SUB.25.318"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Glioblastoma (GBM) is one of the most common and aggressive primary malignant tumors of the central nervous system, accounting for about half of all gliomas in adults. Despite intensive research and advances in molecular biology, genomics, and modern neuroimaging techniques, the prognosis for patients with GBM remains extremely poor. Despite the implementation of multimodal treatment involving surgery, radiotherapy, and chemotherapy with temozolomide, the average survival time of patients is only about 15 months. This is primarily due to the complex biology of this cancer, which involves numerous genetic and epigenetic abnormalities, as well as a highly heterogeneous tumor structure and the presence of glioblastoma stem cells with self renewal capacity. Mutations and abnormalities in genes such as IDH-wt, EGFR, PTEN, TP53, TERT, and CDKN2A\/B are crucial in the pathogenesis of GBM. In particular, IDH-wt status (wild-type isocitrate dehydrogenase) is one of the most important identification markers distinguishing GBM from other, more favorable gliomas with IDH mutations. Frequent EGFR amplifications and TERT gene promoter mutations lead to the deregulation of tumor cell proliferation and increased aggressiveness. In turn, the loss of function of suppressor genes such as PTEN or CDKN2A\/B promotes uncontrolled cell growth and tumor progression. The immunosuppressive tumor microenvironment also plays an important role, promoting immune escape and weakening the effectiveness of systemic therapies, including immunotherapy. The aim of this review is to summarize the current state of knowledge on the epidemiology, classification, pathogenesis, diagnosis, and treatment of glioblastoma multiforme, as well as to discuss the impact of recent advances in molecular and imaging diagnostics on clinical decision-making. A comprehensive review of recent literature (2018\u20132025) was conducted, focusing on WHO CNS5 classification updates, novel biomarkers (IDH, TERT, MGMT, EGFR), and modern diagnostic techniques such as liquid biopsy, radiogenomics, and next-generation sequencing (NGS). The results of the review indicate that the introduction of integrated histo-molecular diagnostics in the WHO 2021 classification has significantly increased diagnostic precision, enabling better prognostic and therapeutic stratification of patients. Modern imaging techniques, such as advanced magnetic resonance imaging (MRI), positron emission tomography (PET), and radiomics and radiogenomics tools, allow for more precise assessment of tumor characteristics, prediction of response to therapy, and monitoring of disease progression. Contemporary molecular techniques, including DNA methylation profiling and NGS, enable in-depth genomic and epigenetic analysis, which translates into a more personalized approach to treatment. Despite the use of multimodal therapy, which is based on maximum safe tumor resection followed by radiotherapy and temozolomide chemotherapy, recurrence is almost inevitable. GBM shows a high degree of resistance to treatment, which results from the presence of stem cell subpopulations, dynamic clonal evolution, and the ability to adapt to unfavorable microenvironmental conditions. Promising preclinical and early clinical results show new therapeutic strategies, including immunotherapy (cancer vaccines, checkpoint inhibitors, CAR-T therapies), oncolytic virotherapy, and Tumor Treating Fields (TTF) technology. Although these methods show potential for prolonging survival, their clinical efficacy still needs to be confirmed in large studies. The role of artificial intelligence in the analysis of imaging and molecular data is also increasingly being emphasized, which may contribute to the development of more accurate predictive models and therapeutic decisions. Despite these advancements, GBM remains a major therapeutic challenge due to its high heterogeneity and treatment resistance. The integration of molecular diagnostics, artificial intelligence, and personalized therapeutic strategies that may enhance survival and quality of life for GBM patients.<\/jats:p>","DOI":"10.3390\/ijms262412162","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:06:56Z","timestamp":1766052416000},"page":"12162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Glioblastoma\u2014A Contemporary Overview of Epidemiology, Classification, Pathogenesis, Diagnosis, and Treatment: A Review Article"],"prefix":"10.3390","volume":"26","author":[{"given":"Kinga","family":"Kr\u00f3likowska","sequence":"first","affiliation":[{"name":"Department of Population Medicine and Lifestyle Diseases Prevention, The Faculty of Medicine, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"B\u0142aszczak","sequence":"additional","affiliation":[{"name":"Department of Population Medicine and Lifestyle Diseases Prevention, The Faculty of Medicine, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6747-2123","authenticated-orcid":false,"given":"S\u0142awomir","family":"\u0141awicki","sequence":"additional","affiliation":[{"name":"Department of Population Medicine and Lifestyle Diseases Prevention, The Faculty of Medicine, Medical University of Bialystok, 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-0722","authenticated-orcid":false,"given":"Monika","family":"Zajkowska","sequence":"additional","affiliation":[{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4854-7155","authenticated-orcid":false,"given":"Monika","family":"Gudowska-Sawczuk","sequence":"additional","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"ref_1","first-page":"3","article-title":"Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jacome, M.A., Wu, Q., Pi\u00f1a, Y., and Etame, A.B. (2024). Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma. Cancers, 16.","DOI":"10.3390\/cancers16213635"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.ejca.2011.12.013","article-title":"Epidemiology of glial and non-glial brain tumours in Europe","volume":"48","author":"Crocetti","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102078","DOI":"10.1016\/j.canep.2021.102078","article-title":"Racial\/ethnic and sex differences in young adult malignant brain tumor incidence by histologic type","volume":"76","author":"Monterroso","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"ref_8","first-page":"546","article-title":"Economic income and survival in patients affected by glioblastoma: A systematic review and meta-analysis","volume":"11","author":"Gatto","year":"2024","journal-title":"Neurooncol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: A review on the impact of treatment modalities","volume":"18","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1172\/JCI71048","article-title":"Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males","volume":"124","author":"Sun","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","article-title":"Paediatric and adult malignant glioma: Close relatives or distant cousins?","volume":"9","author":"Jones","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","unstructured":"WHO Classification of Tumours Editorial Board (2021). WHO Classification of Tumours of the Central Nervous System, WHO Classification of Tumours Editorial Board. [5th ed.]. CNS5."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40478-023-01605-x","article-title":"On the origin and development of glioblastoma: Multifaceted role of perivascular mesenchymal stromal cells","volume":"11","author":"Khettab","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s44276-024-00051-z","article-title":"Viruses in glioblastoma: An update on evidence and clinical trials","volume":"2","author":"Gunasegaran","year":"2024","journal-title":"BJC Rep."},{"key":"ref_16","first-page":"85","article-title":"Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors","volume":"6","author":"Testa","year":"2018","journal-title":"Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00401-021-02337-9","article-title":"TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma","volume":"142","author":"Fujimoto","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Olympios, N., Gilard, V., Marguet, F., Clatot, F., Di Fiore, F., and Fontanilles, M. (2021). TERT Promoter Alterations in Glioblastoma: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13051147"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rodriguez, S.M.B., Kamel, A., Ciubotaru, G.V., Onose, G., Sevastre, A.S., Sfredel, V., Danoiu, S., Dricu, A., and Tataranu, L.G. (2023). An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311110"},{"key":"ref_20","first-page":"1141","article-title":"Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas","volume":"21","author":"Fan","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., and Saoud, K. (2018). The p53 Pathway in Glioblastoma. Cancers, 10.","DOI":"10.3390\/cancers10090297"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","article-title":"Gain of function of mutant TP53 in glioblastoma: Prognosis and response to temozolomide","volume":"21","author":"Wang","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","first-page":"90","article-title":"The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas","volume":"38","author":"Terzi","year":"2022","journal-title":"Turk Patoloji Derg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","article-title":"Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Becker, A.P., Sells, B.E., Haque, S.J., and Chakravarti, A. (2021). Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers, 13.","DOI":"10.3390\/cancers13040761"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.3390\/cimb46090588","article-title":"Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance","volume":"46","author":"Tataranu","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e009175","DOI":"10.1136\/jitc-2024-009175","article-title":"Co-evolution of glioma and immune microenvironment","volume":"12","author":"Elguindy","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Agosti, E., Antonietti, S., Ius, T., Fontanella, M.M., Zeppieri, M., and Panciani, P.P. (2024). Glioma Stem Cells as Promoter of Glioma Progression: A Systematic Review of Molecular Pathways and Targeted Therapies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147979"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-016-0709-8","article-title":"Current and future strategies for treatment of glioma","volume":"40","author":"Bush","year":"2017","journal-title":"Neurosurg. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sipos, D., Raposa, B.L., Freihat, O., Simon, M., Mekis, N., Cornacchione, P., and Kov\u00e1cs, \u00c1. (2025). Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17010146"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1517\/14728220902942348","article-title":"Glioblastoma multiforme: A review of therapeutic targets","volume":"13","author":"Kanu","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sipos, D., Debreczeni-M\u00e1t\u00e9, Z., Ritter, Z., Freihat, O., Simon, M., and Kov\u00e1cs, \u00c1. (2024). Complex Diagnostic Challenges in Glioblastoma: The Role of 18F-FDOPA PET Imaging. Pharmaceuticals, 17.","DOI":"10.3390\/ph17091215"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.2174\/0929867324666170516123206","article-title":"Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review","volume":"24","author":"Batash","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Debreczeni-M\u00e1t\u00e9, Z., Freihat, O., T\u00f6r\u0151, I., Simon, M., Kov\u00e1cs, \u00c1., and Sipos, D. (2024). Value of 11C-Methionine PET Imaging in High-Grade Gliomas: A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16183200"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-014-1404-7","article-title":"Imaging guidelines and findings of extracranial glioblastoma","volume":"118","author":"Ginat","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kokkinos, V., Chatzisotiriou, A., and Seimenis, I. (2023). Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging-Tractography in Resective Brain Surgery: Lesion Coverage Strategies and Patient Outcomes. Brain Sci., 13.","DOI":"10.3390\/brainsci13111574"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11940-017-0469-y","article-title":"Functional MRI for Surgery of Gliomas","volume":"19","author":"Castellano","year":"2017","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: Version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","first-page":"tzad004","article-title":"State of the art: Radiomics and radiomics-related artificial intelligence on the road to clinical translation","volume":"6","author":"Majumder","year":"2024","journal-title":"BJR Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: Recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e13107","DOI":"10.1111\/bpa.13107","article-title":"Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas","volume":"32","author":"Liu","year":"2022","journal-title":"Brain Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-020-03677-4","article-title":"Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review","volume":"152","author":"Lee","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"735659","DOI":"10.1155\/2014\/735659","article-title":"Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia","volume":"2014","author":"Polivka","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, G.T., Liu, Q., Zuo, F.X., Liu, H.J., Wang, S.Q., Yuan, Q., Liu, A.S., Hu, K., Meng, X.L., and Wang, W.J. (2023). Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10541-x"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae Insights: Central Nervous System Cancers, Version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, C., Li, K., Deng, J., Liu, H., Lai, G., Xie, B., and Zhong, X. (2023). Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015465"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e28174","DOI":"10.1016\/j.heliyon.2024.e28174","article-title":"Landscape of infiltrated immune cell characterization in COVID-19","volume":"10","author":"Zheng","year":"2024","journal-title":"Heliyon"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0042-1750067","article-title":"Histopathological Profile of Central Nervous System Tumors in a Peripheral Tertiary Care Centre of West Bengal","volume":"15","author":"Bhattacharya","year":"2023","journal-title":"J. Lab. Physicians"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5306\/wjco.v13.i7.567","article-title":"Simple approach for the histomolecular diagnosis of central nervous system gliomas based on 2021 World Health Organization Classification","volume":"13","author":"Kurdi","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lan, Z., Li, X., and Zhang, X. (2024). Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25053040"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Saenz-Anto\u00f1anzas, A., Auzmendi-Iriarte, J., Carrasco-Garcia, E., Moreno-Cugnon, L., Ruiz, I., Villanua, J., Ega\u00f1a, L., Otaegui, D., Sampr\u00f3n, N., and Matheu, A. (2019). Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges. Cancers, 11.","DOI":"10.3390\/cancers11070950"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.annonc.2025.02.005","article-title":"ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma","volume":"36","author":"Lorca","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"Mayor","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_61","first-page":"iv1","article-title":"Artificial Intelligence, Radiomics, and Deep Learning in Neuro-Oncology","volume":"2","author":"Galldiks","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3174\/ajnr.A7029","article-title":"MRI-Based Deep-Learning Method for Determining Glioma MGMT Promoter Methylation Status","volume":"42","author":"Yogananda","year":"2021","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1148\/radiol.2016161382","article-title":"Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features","volume":"281","author":"Kickingereder","year":"2016","journal-title":"Radiology"},{"key":"ref_64","first-page":"127","article-title":"Artificial intelligence in cancer imaging: Clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zlochower, A., Chow, D.S., Chang, P., Khatri, D., Boockvar, J.A., and Filippi, C.G. (2020). Deep Learning AI Applications in the Imaging of Glioma. Top. Magn. Reson. Imaging, 29.","DOI":"10.1097\/RMR.0000000000000237"},{"key":"ref_66","first-page":"vdae159","article-title":"Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O6-methylguanine-methyltransferase promoter methylation status","volume":"6","author":"Yadav","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41416-021-01387-w","article-title":"Radiomics and radiogenomics in gliomas: A contemporary update","volume":"125","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_68","unstructured":"Debinski, W. (2021). Gliomas, Exon Publications."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s13167-024-00374-4","article-title":"Artificial intelligence in ovarian cancer drug resistance advanced 3PM approach: Subtype classification and prognostic modeling","volume":"15","author":"Zhang","year":"2024","journal-title":"EPMA J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2019190913","article-title":"Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma","volume":"2","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Buzdugan, S., Mazher, M., and Puig, D. (2025). Radiogenomics for Glioblastoma Survival Prediction: Integrating Radiomics, Clinical, and Genomic Features Using Artificial Intelligence. J. Imaging Inform. Med.","DOI":"10.1007\/s10278-025-01692-3"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"274ra19","DOI":"10.1126\/scitranslmed.aaa2384","article-title":"Intraoperative brain cancer detection with Raman spectroscopy in humans","volume":"7","author":"Jermyn","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Elliot, M., S\u00e9gaud, S., Lavrador, J.P., Vergani, F., Bhangoo, R., Ashkan, K., Xie, Y., Stasiuk, G.J., Vercauteren, T., and Shapey, J. (2025). Fluorescence Guidance in Glioma Surgery: A Narrative Review of Current Evidence and the Drive Towards Objective Margin Differentiation. Cancers, 17.","DOI":"10.3390\/cancers17122019"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/neuros\/nyx271","article-title":"Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Nonenhancing Gliomas","volume":"82","author":"Bowden","year":"2018","journal-title":"Neurosurgery"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.csbj.2024.11.007","article-title":"Rapid intraoperative amplicon sequencing of CNS tumor markers","volume":"26","author":"Evers","year":"2024","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ivanov, S., Nano, O., Hana, C., Bonano-Rios, A., and Hussein, A. (2024). Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137337"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","article-title":"What is next generation sequencing?","volume":"98","author":"Behjati","year":"2013","journal-title":"Arch. Dis. Child. Educ. Pract. Ed."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41416-021-01536-1","article-title":"NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types","volume":"126","author":"Rolfo","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"166534","DOI":"10.1016\/j.bbadis.2022.166534","article-title":"Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression","volume":"1868","author":"Chen","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"200876","DOI":"10.1016\/j.omton.2024.200876","article-title":"Innovative approaches to glioma treatment: Oncolytic foamy virus and CAR T cell therapy","volume":"32","author":"Amhis","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Vandecandelaere, G., Ramapriyan, R., Gaffey, M., Richardson, L.G., Steuart, S.J., Tazhibi, M., Kalaw, A., Grewal, E.P., Sun, J., and Curry, W.T. (2024). Pre-Clinical Models for CAR T-Cell Therapy for Glioma. Cells, 13.","DOI":"10.3390\/cells13171480"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Shan, K.S., Musleh Ud Din, S., Dalal, S., Gonzalez, T., Dalal, M., Ferraro, P., Hussein, A., and Vulfovich, M. (2025). Bispecific Antibodies in Solid Tumors: Advances and Challenges. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125838"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Alomari, O., Eyvazova, H., G\u00fcney, B., Al Juhmani, R., Odabasi, H., Al-Rawabdeh, L., Mokresh, M.E., Erginoglu, U., Keles, A., and Baskaya, M.K. (2025). Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17152550"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rousseau, J., Lapointe, S., and Roberge, D. (2025). Tumor-Treating Fields and Related Treatments in the Management of Pediatric Brain Tumors. Curr Oncol., 32.","DOI":"10.3390\/curroncol32040185"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.2147\/JMDH.S557248","article-title":"Oncolytic Virotherapy for Glioma: A Bibliometric Roadmap for Multidisciplinary Clinical and Research Strategies","volume":"18","author":"Liu","year":"2025","journal-title":"J Multidiscip. Healthc."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Manganelli, V., Misasi, R., Riitano, G., Capozzi, A., Mattei, V., Caglar, T.R., Ialongo, D., Madia, V.N., Messore, A., and Costi, R. (2023). Role of a Novel Heparanase Inhibitor on the Balance between Apoptosis and Autophagy in U87 Human Glioblastoma Cells. Cells, 12.","DOI":"10.3390\/cells12141891"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:08:34Z","timestamp":1766052514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":88,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412162"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412162","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}